N-trimethyl chitosan (TMC)-modified microemulsions for improved oral bioavailability of puerarin: preparation and evaluation. 2015

Dehua Liao, and Xinyi Liu, and Wei Dai, and Tiantian Tang, and Ge Ou, and Kai Zhang, and Meng Han, and Rongrong Kang, and Sufang Yang, and Daxiong Xiang
Department of Pharmacy, The Second Xiangya Hospital of Central South University , Changsha , China .

The aim of this research was to increase the oral bioavailability of puerarin by N-trimethyl chitosan-modified microemulsions (TMC-MEs) loaded with puerarin. Different concentrations of TMC-modified microemulsions were prepared in our study, and then evaluated for particle size, zeta potential, morphological observation and changes of the microenvironment polarity of inner oil core. It was shown that the zeta potential of the microemulsion was increased with the increasing concentration of TMC, and the peak value was achieved when the concentration of TMC was 3.0 mg/mL. The enhancement of the ratio of I(1)/I(3) (the ratio between the first band and the third band of the emission fluorescence spectrum of pyrene, I(1) = 373 nm, I(3) = 384 nm) indicated that polarity of the inner core of TMC-MEs was increased with the addition of the modifier. Pharmacokinetic studies demonstrated that after oral administration of puerarin N-trimethyl chitosan (TMC)-modified microemulsions (PUE-TMEs) and puerarin microemulsions (PUE-MEs) to rats at a dose of 100 mg/kg, relative bioavailability was enhanced about 6.8- and 1.2-fold, respectively, compared to puerarin suspension (PUE-SUS) as control. It indicated that the TMC-MEs could be used as an effective formulation for enhancing the oral bioavailability of puerarin.

UI MeSH Term Description Entries
D007529 Isoflavones 3-Phenylchromones. Isomeric form of FLAVONOIDS in which the benzene group is attached to the 3 position of the benzopyran ring instead of the 2 position. 3-Benzylchroman-4-One,3-Benzylidene-4-Chromanone,Homoisoflavone,Homoisoflavones,Isoflavone,Isoflavone Derivative,3-Benzylchroman-4-Ones,3-Benzylidene-4-Chromanones,Isoflavone Derivatives,3 Benzylchroman 4 One,3 Benzylchroman 4 Ones,3 Benzylidene 4 Chromanone,3 Benzylidene 4 Chromanones,Derivative, Isoflavone,Derivatives, Isoflavone
D008297 Male Males
D010316 Particle Size Relating to the size of solids. Particle Sizes,Size, Particle,Sizes, Particle
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D004655 Emulsions Colloids formed by the combination of two immiscible liquids such as oil and water. Lipid-in-water emulsions are usually liquid, like milk or lotion. Water-in-lipid emulsions tend to be creams. The formation of emulsions may be aided by amphiphatic molecules that surround one component of the system to form MICELLES. Emulsion
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats

Related Publications

Dehua Liao, and Xinyi Liu, and Wei Dai, and Tiantian Tang, and Ge Ou, and Kai Zhang, and Meng Han, and Rongrong Kang, and Sufang Yang, and Daxiong Xiang
November 2012, Drug development and industrial pharmacy,
Dehua Liao, and Xinyi Liu, and Wei Dai, and Tiantian Tang, and Ge Ou, and Kai Zhang, and Meng Han, and Rongrong Kang, and Sufang Yang, and Daxiong Xiang
November 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Dehua Liao, and Xinyi Liu, and Wei Dai, and Tiantian Tang, and Ge Ou, and Kai Zhang, and Meng Han, and Rongrong Kang, and Sufang Yang, and Daxiong Xiang
November 2008, International journal of pharmaceutics,
Dehua Liao, and Xinyi Liu, and Wei Dai, and Tiantian Tang, and Ge Ou, and Kai Zhang, and Meng Han, and Rongrong Kang, and Sufang Yang, and Daxiong Xiang
May 2018, Journal of controlled release : official journal of the Controlled Release Society,
Dehua Liao, and Xinyi Liu, and Wei Dai, and Tiantian Tang, and Ge Ou, and Kai Zhang, and Meng Han, and Rongrong Kang, and Sufang Yang, and Daxiong Xiang
May 2019, Current eye research,
Dehua Liao, and Xinyi Liu, and Wei Dai, and Tiantian Tang, and Ge Ou, and Kai Zhang, and Meng Han, and Rongrong Kang, and Sufang Yang, and Daxiong Xiang
November 2011, Drug delivery,
Dehua Liao, and Xinyi Liu, and Wei Dai, and Tiantian Tang, and Ge Ou, and Kai Zhang, and Meng Han, and Rongrong Kang, and Sufang Yang, and Daxiong Xiang
July 2020, International journal of biological macromolecules,
Dehua Liao, and Xinyi Liu, and Wei Dai, and Tiantian Tang, and Ge Ou, and Kai Zhang, and Meng Han, and Rongrong Kang, and Sufang Yang, and Daxiong Xiang
July 2020, Carbohydrate research,
Dehua Liao, and Xinyi Liu, and Wei Dai, and Tiantian Tang, and Ge Ou, and Kai Zhang, and Meng Han, and Rongrong Kang, and Sufang Yang, and Daxiong Xiang
March 2016, Colloids and surfaces. B, Biointerfaces,
Dehua Liao, and Xinyi Liu, and Wei Dai, and Tiantian Tang, and Ge Ou, and Kai Zhang, and Meng Han, and Rongrong Kang, and Sufang Yang, and Daxiong Xiang
September 2019, International journal of pharmaceutics,
Copied contents to your clipboard!